"Arming" the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours

Ítems similars

• Arming the oncolytic virus enadenotucirev (EnAd) to generate enhanced locally-acting immunotherapies for cancer
  per: Champion, Brian R, et al.
  Publicat: (2015)
• Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
  per: Illingworth, Sam, et al.
  Publicat: (2017)
• Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
  per: Rocio Garcia-Carbonero, et al.
  Publicat: (2017-09-01)
• Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
  per: Garcia-Carbonero, Rocio, et al.
  Publicat: (2017)
• Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth
  per: Tedcastle, Alison, et al.
  Publicat: (2016)